Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

JAMA Network Open(2020)10.1001/jamanetworkopen.2020.3284Source: DataRank Database

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017 is a research paper published in JAMA Network Open (2020). On theSindex it has a DataRank of 0. It has been cited 121 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access121 citations

Download PDF

Cite:

Linked data & code

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 13.83)OA: goldTopics (24)Linked Datasets (10)DataCite Reuse (10)IDs (PubMed, PMC, OpenAlex)

FAIR Checklist

Context only (not used in score)

Findable (2/2)

Has DOI
Indexed in repositories

Accessible (1/2)

Open Access

Interoperable (2/2)

DataCite relations
Linked datasets

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Jeremy Puthumana ORCID,Nicholas S. Downing,Nilay D. Shah ORCID,Harlan M. Krumholz ORCID,Joseph S. Ross ORCID

Live enrichment

PubMed:32315070 PMC:PMC7175081 OpenAlex:https://openalex.org/W3017195870

NCATS NIH HHS

Grant: UL1 TR001863

FWCI

13.83

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by

journalhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2764603/zhang_2020_oi_200159.pdf

publisherhttps://jamanetwork.com/journals/jamanetworkopen/articlepdf/2764603/zhang_2020_oi_200159.pdf

journalhttps://doi.org/10.1001/jamanetworkopen.2020.3284

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32315070

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/7175081

Fields of Study

Statistical Methods in Clinical TrialsHealth Systems, Economic Evaluations, Quality of LifePharmaceutical Economics and Policy

MeSH Terms

Biological ProductsClinical Trials as TopicCross-Sectional StudiesPharmaceutical PreparationsHumansUnited StatesUnited States Food and Drug AdministrationDrug Approval

Keywords

MedicineFood and drug administrationClinical trialDrug approvalBlindingBioequivalenceOrphan drugDrugApproved drugPharmacologyInternal medicinePharmacokineticsBioinformatics

Additional file 2 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869885.v1figshare

Additional file 2 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869885figshare

Additional file 3 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869888figshare

Additional file 3 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869888.v1figshare

Additional file 5 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869894.v1figshare

Additional file 4 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869891.v1figshare

Additional file 4 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869891figshare

Additional file 1 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869882.v1figshare

Additional file 1 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869882figshare

Additional file 5 of Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018

10.6084/m9.figshare.17869894figshare